FDA Panel Recommends Pulling Preterm Birth Drug From the Market
The agency has weighed years of study that showed the treatment given accelerated approval 11 years ago was not effective.
Call for more information
888-531-0245
info@siii-clinical.com
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.